Cas:1020720-09-5 1-bromo-2,3,4,5-tetradeuterio-6-nitrobenzene manufacturer & supplier

Chemical Name:1-bromo-2,3,4,5-tetradeuterio-6-nitrobenzene

CAS.NO:1020720-09-5

Synonyms:2-Bromonitrobenzene-d4;1-Bromo-2-nitrobenzene-d4;2-Nitrobromobenzene-d4;1-Bromo-2-nitrobenze-d4;2-Nitrophenyl-d4 Bromide

Molecular Formula:C₆BrD₄NO₂

Molecular Weight:206.03000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:45.82000

Exact Mass:204.96800

LogP:2.88050

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3459 6.1 / PGIII

Packing Group:

Contact us for information like 2-Bromonitrobenzene-d4 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Nitrophenyl-d4 Bromide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-Bromo-2-nitrobenze-d4 Use and application,2-Bromonitrobenzene-d4 technical grade,usp/ep/jp grade.

Related News: In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. 1-bromo-2,3,4,5-tetradeuterio-6-nitrobenzene manufacturer In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. 1-bromo-2,3,4,5-tetradeuterio-6-nitrobenzene supplier Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 1-bromo-2,3,4,5-tetradeuterio-6-nitrobenzene vendor Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 1-bromo-2,3,4,5-tetradeuterio-6-nitrobenzene factory In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.